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Abstract
Introduction: The HIV prevention cascade could be used in developing interventions to strengthen implementation of effica-
cious HIV prevention methods, but its practical utility needs to be demonstrated. We propose a standardized approach to
using the cascade to guide identification and evaluation of interventions and demonstrate its feasibility for this purpose
through a project to develop interventions to improve HIV prevention methods use by adolescent girls and young women
(AGYW) and potential male partners in east Zimbabwe.
Discussion: We propose a six-step approach to using a published generic HIV prevention cascade formulation to develop
interventions to increase motivation to use, access to and effective use of an HIV prevention method. These steps are as fol-
lows: (1) measure the HIV prevention cascade for the chosen population and method; (2) identify gaps in the cascade; (3) iden-
tify explanatory factors (barriers) contributing to observed gaps; (4) review literature to identify relevant theoretical
frameworks and interventions; (5) tailor interventions to the local context; and (6) implement and evaluate the interventions
using the cascade steps and explanatory factors as outcome indicators in the evaluation design. In the Zimbabwe example,
steps 1-5 aided development of four interventions to overcome barriers to effective use of pre-exposure prophylaxis (PrEP) in
AGYW (15-24 years) and voluntary medical male circumcision in male partners (15-29). For young men, prevention cascade
analyses identified gaps in motivation and access as barriers to voluntary medical male circumcision uptake, so an intervention
was designed including financial incentives and an education session. For AGYW, gaps in motivation (particularly lack of risk
perception) and access were identified as barriers to PrEP uptake: an interactive counselling game was developed addressing
these barriers. A text messaging intervention was developed to improve PrEP adherence among AGYW, addressing reasons
underlying lack of effective PrEP use through improving the capacity (“skills”) to take PrEP effectively. A community-led inter-
vention (community conversations) was developed addressing community-level factors underlying gaps in motivation, access
and effective use. These interventions are being evaluated currently using outcomes from the HIV prevention cascade (step 6).
Conclusions: The prevention cascade can guide development and evaluation of interventions to strengthen implementation of
HIV prevention methods by following the proposed process.
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1 | INTRODUCTION
HIV prevention cascades may facilitate identification and
understanding of gaps in use of primary HIV prevention meth-
ods and identification and evaluation of interventions to
address the gaps [1-4].
While HIV treatment cascades – describing the steps
required to achieve viral suppression [5] – have aided design
of interventions to improve treatment programmes (e.g. in
Uganda [6]) and cascades are utilized in prevention of
mother-to-child HIV transmission programmes [7],
formulations of the HIV prevention cascade have been largely
theoretical and its utility in identifying appropriate interven-
tions remains to be demonstrated [1-4,8-14]. We present a
standardized approach to using the prevention cascade to
guide identification, development and evaluation of interven-
tions to increase effective use of HIV prevention methods. We
demonstrate the feasibility of this approach by describing the
development and pilot testing of interventions to reduce HIV
risk among adolescent girls and young women (AGYW) in
Manicaland, east Zimbabwe – moving prevention cascades
from theory into practice.
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2 | DISCUSSION
2.1 | HIV prevention cascade framework
Our preferred HIV prevention cascade framework –
developed through multiple consultations [15] – focuses on
three domains for prevention method use in a priority at-risk
population: motivation, access and effective use (Figure 1A).
Effective use is the uptake and adherence required to achieve
close to the maximum level of protection against HIV infection
afforded by the method. The gap between access and effec-
tive use reflects lack of capacity to use the method effectively.
Justification of this framework is available [4]. Key features
and advantages are as follows: (1) it is generic so can be
applied for any primary prevention method(s) or population;
(2) effective use – the endpoint of the cascade – is closely
aligned with impact (HIV infections averted); (3) it provides a
simple core cascade for high-level monitoring and advocacy;
(4) ease of application to combination HIV prevention; and (5)
it reflects that multiple barriers work together limiting effec-
tive use of HIV prevention methods.
2.2 | Standard approach to using the HIV
prevention cascade to develop interventions
We propose a series of steps to be followed in using the HIV
prevention cascade to identify and evaluate potentially effec-
tive interventions to improve use of HIV prevention methods
and reduce HIV incidence in an at-risk population:
1. Measure the HIV prevention cascade for the chosen popu-
lation and method(s)
2. Examine the three steps in the cascade to identify gaps in
use of the method(s), thereby identifying broad targets for
interventions
3. Use the best available data on the factors contributing to
the gaps identified in the cascade (the sub-bars in Fig-
ure 1A) to establish which specific barriers should be tar-
geted to increase effective use of the method(s)
4. Review the literature to identify theoretical frameworks
and interventions that have potential to reduce the factors
identified as barriers to effective use
5. Tailor the interventions to the local epidemiological and
socio-economic context
6. Implement the interventions, including the steps and
explanatory factors in the HIV prevention cascade as out-
comes in the evaluation design
The prevention cascade supports the identification of inter-
vention targets but does not impose specific intervention
designs.
2.3 | Practical examples from Manicaland
2.3.1 | Setting and epidemiological context
The HIV prevention cascade is guiding research to develop
interventions to reduce HIV incidence in AGYW in Manicaland
by increasing effective use of HIV prevention methods includ-
ing voluntary medical male circumcision (VMMC) in male part-
ners and oral pre-exposure prophylaxis (PrEP) in AGYW.
Manicaland is a rural [16] province that has been identified
as an HIV transmission “hotspot” [17] and is a priority area
in the Zimbabwe National HIV and AIDS Strategic Plan [18].
Adult (15+) HIV prevalence declined from over 25% in the
late 1990s to 11% in 2015-2016 [19]. HIV incidence fell
from 1.8% in the mid-2000s to under 1% among females and
0.5% among males [20], partially due to behaviour change
[21,22]. HIV prevalence among AGYW (5.4%) in Manicaland
is nearly double that of young men (2.9%) [23]. HIV inci-
dence among AGYW remains high (1.4% 2009 to 2013) [20].
AGYW in Manicaland commonly have sexual relationships
with older men while condom use is low [24]. Oral PrEP is
only available in small-scale research projects [25]. Zimbabwe
is a priority country in the DREAMS programme [26]. Mani-
caland is a priority for PrEP introduction for key populations,
including AGYW [27]. VMMC uptake in Manicaland has been
slow [28].
2.3.2 | Selection of interventions
The study (Manicaland Study) commenced in July 2018 to
identify and test interventions to reduce multi-level barriers
preventing AGYW at risk of HIV infection and potential male
partners from using efficacious prevention methods. The study
is being implemented in eight sites in Manicaland representing
different socio-economic strata; VMMC and PrEP were
selected being relatively new methods of HIV prevention with
high efficacy and potential to contribute more to the overall
impact of combination prevention in Zimbabwe.
Data collected between 1998 and 2013 in a general-popu-
lation cohort study (Manicaland Cohort) [20] were used to
measure the preliminary HIV prevention cascades [2,4] (step
1) and identify gaps in motivation, access, and effective use of
PrEP and VMMC in AGYW and their male sexual partners
(step 2). Cohort data were analysed to establish which specific
barriers to effective use of these methods should be targeted
by interventions (step 3). These analyses arranged existing
Manicaland Cohort data into this framework. Interventions
were identified using behavioural economics and community
psychology literature (step 4), and developed and tailored to
the local context (step 5) using information from previous
studies [24,29], including qualitative analyses [30,31]. These
interventions are being pilot tested using a cluster-randomized
controlled trial design with matched intervention and control
clusters in each of the study sites. Indicators based on the
HIV prevention cascade are being used as outcomes in this
evaluation study. Further details are available at https://clinical
trials.gov (NCT03565575 and NCT03565588).
The study includes three individual-based interventions, in
eight study sites, and a community-based intervention
implemented in two of these sites. The study addresses indi-
vidual- and community-level barriers to HIV prevention use
– recognizing that HIV prevention behaviour is influenced
by multiple factors acting at different levels [32-34].
Intervention 1: Increasing young men’s motivation for and
access to VMMC
Increasing effective use of VMMC helps to reduce HIV inci-
dence in AGYW by reducing exposure to HIV infection from
their male partners. VMMC is central in Zimbabwe’s HIV pre-
vention programme, but only 10% of men (15-49) are
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circumcised in Manicaland [23] and uptake is off-track to meet
national targets [28].
Previous HIV prevention cascade analysis using Manicaland
Cohort data found that low VMMC uptake in the study popu-
lation was largely due to low risk perception for HIV infection,
suggesting gaps in motivation and poor local availability [2].
Motivation for VMMC uptake can be affected by negative
perceptions of its consequences. Transport costs and lost
income were identified as important barriers to access
(Figure 1B).
An intervention was developed where HIV-negative young
men (15-29) participate in an education session on HIV risks
and reducing these risks through VMMC, run by a circum-
cised male “role-model.” They are randomized to receive a
fixed financial reward or the opportunity to participate in a
lottery (with financial rewards) upon VMMC uptake. Partici-
pants receive a contribution towards transport costs for
accessing VMMC and are referred to participating study
clinics offering VMMC. The education session aims to
increase motivation by improving HIV risk perception, knowl-
edge and perceptions about consequences of VMMC. The
financial incentive increases motivation by creating more
positive consequences for uptake. Previous behavioural eco-
nomics research showed lottery tickets may be more effec-
tive in increasing motivation than fixed financial rewards as
individuals overweight small probability events [35]. For
access to VMMC, the education session and referral provide
information about local availability; the financial incentives
and contribution towards transport costs improve its afford-
ability.
Organizing the follow-up data in the prevention cascade
framework aids evaluation by providing data on possible rea-
sons why the intervention may have failed to improve uptake.
Changes in the HIV prevention cascade for VMMC will be
compared between a baseline and follow-up survey six months
later, for men in the intervention and control groups using
HIV risk perception and VMMC uptake as primary outcomes.
Intervention 2: Increasing motivation and access for PrEP
use among AGYW
No prior measurements of the HIV prevention cascade for
PrEP were available for AGYW in the study population. Since
PrEP is a new method of HIV prevention in Zimbabwe and is
not widely available [25], it was assumed that motivation,
access and effective use would be low at the outset.
Earlier analyses of Manicaland Cohort data on risk among
AGYW indicated unprotected sexual relationships with older
men contribute to their high HIV incidence [24]. Preliminary
analyses of the HIV prevention cascade for other prevention
methods among AGYW found gaps in perceptions about
personal HIV infection risks [2,4]. Lack of risk perception indi-
cates lack of motivation to use HIV prevention methods. Evi-
dence from population-based trials on PrEP in sub-Saharan
Africa suggests low risk perception may limit PrEP use along
with doubt about using antiretroviral drugs (ARVs) for preven-
tion [36-38].
An intervention was designed whereby HIV-negative AGYW
(18-24) play an interactive counselling game [39], addressing
optimistic beliefs about HIV infection risks – particularly
around sexual relations with older men – and providing infor-
mation on the nature, effectiveness, tolerability and local avail-
ability of PrEP. Participants can choose to be contacted by a
nurse to discuss PrEP further and a referral letter to partici-
pating study clinics where PrEP services are available. The
intervention aims to adjust HIV risk perception and improve
PrEP uptake by targeting barriers in motivation and access to
use (Figure 1C). Gaps in motivation are addressed by improv-
ing knowledge of the method and consequences of its use and
increasing risk perception accuracy. Previous studies showed
that providing disaggregated information on HIV risks can
adjust risk perception and behaviour [39,40]. Information on
and referrals to local PrEP services address gaps in access.
Evaluation will compare the HIV prevention cascades for
PrEP for AGYW in the intervention and control groups after
six months using HIV risk perception and uptake of PrEP (con-
firmed by ARV presence in blood samples [41-43]) as primary
outcomes.
Intervention 3: Increasing effective use of PrEP by AGYW
Effective use of PrEP requires continuous adherence – not
just uptake – to provide protection against HIV infection. It is
anticipated that this will be a challenge for AGYW [44].
AGYW may have difficulties remembering to take PrEP daily
and could lack salience about the risks and consequences of
HIV infection.
An intervention was designed to improve PrEP adherence
among AGYW who are on PrEP whereby they receive unidi-
rectional, personalized text messages, acting as “nudges.” Text
messaging “nudges” have been shown to improve ART adher-
ence [45]. This intervention addresses the likely gaps in per-
sonal capacity to use PrEP effectively, specifically limited
salience of HIV risk (Figure 1C), thus improving the “skills”
required to adhere consistently. Knowledge of these remin-
ders may improve the self-perceived ability to adhere to PrEP
(self-efficacy).
This intervention will be evaluated by randomizing AGYW
on PrEP into intervention and control groups. Effective use of
PrEP (adherence assessed through self-reports and ARV pres-
ence in blood samples) will be compared in the two groups
after six months.
Figure 1. The generic HIV prevention cascade framework used in this study (A) to guide the design of interventions to improve HIV preven-
tion use among adolescent boys and young men (15-29) (B) and adolescent girls and young women (18-24) (C)
The generic prevention cascade includes the core steps of the cascade (green) and the major reasons underlying gaps in the core steps (orange),
which provide links to interventions to improve motivation, access, and effective use. The specific interventions referred to in (A,B) are an educa-
tion session by a circumcised health worker and financial incentives to take up voluntary medical male circumcision (VMMC) (intervention 1), an
interactive counselling game to improve risk perception and pre-exposure prophylaxis (PrEP) uptake (intervention 2), weekly text message remin-
ders to improve PrEP adherence (intervention 3), and community conversation (intervention 4).
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Intervention 4: Improving social support for young people’s
use of HIV prevention methods
Some factors contributing to gaps in the cascade lie outside
of the individual’s control, including influences by partners,
peers, families, healthcare providers and social structures [32].
Prevention cascade analysis of the study population showed
social norms and partner disapproval represent barriers to
condom use [4]. Individual-level interventions may have limited
impact in increasing effective VMMC and PrEP use if the local
social environment is not supportive.
A community conversations (CCs) intervention [46] is being
implemented in two study sites to address community-level
barriers contributing to the HIV prevention cascades for
VMMC and PrEP. CCs are a community-led capacity-building
process where community members identify, plan, implement
and evaluate their own actions to break down community-
level barriers to engagement with HIV prevention methods.
CCs are expected to improve motivation for HIV prevention
method use by creating and fostering supportive social norms
(Figure 1B,C). Partner approval – an important factor for PrEP
use [47] and VMMC [48] – is being addressed. Creating more
prevention-positive social norms in a community may encour-
age health workers to adopt less stigmatizing attitudes
towards HIV prevention use by young people, making provi-
sion of HIV prevention services more acceptable and improv-
ing access.
Survey and qualitative data will be analysed to evaluate
whether the CCs intervention impacted the specific barriers
to motivation, access and effective use of PrEP and VMMC by
AGYW and young men in the study populations. Prevention
cascades will be constructed and compared for VMMC and
PrEP in the intervention and control groups between the two
CCs sites and the remaining six sites to assess the effective-
ness of CCs.
3 | CONCLUSIONS
We have outlined a generic approach to using the HIV pre-
vention cascade to identify, develop and evaluate interventions
and demonstrated feasibility of application using the example
of a study testing interventions to strengthen implementation
of VMMC and PrEP services in Manicaland.
When developing interventions, a central benefit of the HIV
prevention cascade framework is that it underscores the mul-
titude of factors to be addressed potentially limiting effective
use of prevention methods. As with PrEP in Manicaland, the
prevention cascade framework is useful for organizing evi-
dence from other methods and settings to guide thinking
about barriers to be addressed in implementing a new
method. While the cascade highlights bottlenecks and areas
that require interventions to improve progress through the
cascade, it does not determine the most suitable interventions
– these must be based on theoretical frameworks, local cir-
cumstances and evidence from similar settings.
When evaluating interventions, outcomes and process indi-
cators can be defined corresponding to steps and reasons
underlying gaps in the HIV prevention cascade, providing a
standardized basis to compare intervention and control
groups and over time. Cascade analysis can be useful for
interpretation of trial results and identifying reasons for the
success or failure of interventions. The HIV prevention cas-
cade does not measure the impact of interventions. This is
possible – as planned in the Manicaland Study – by mathemat-
ical modelling to generate estimates of population-level
impact. The cascade is being used in evaluating the implemen-
tation of individual and combination HIV prevention methods
to estimate the overall impact of the interventions on HIV
incidence.
In the Manicaland Study, the HIV prevention cascade is
being measured and interpreted using data from population
surveys and qualitative investigations. Other data sources –
for example, routinely collected health data – could also be
used (see [4] for further discussion).
Evaluation of the aforementioned interventions has not
been completed. Nevertheless, the study demonstrates the
HIV prevention cascade framework can be used to improve
development and evaluation of HIV prevention interventions
by setting targets to be addressed to remove bottlenecks in
prevention use. The framework can be used for multiple set-
tings, populations and HIV prevention methods as it is generic
and adaptable by design, although the risk of stigmatizing
specific populations (e.g. AGYW) should be considered. As the
HIV treatment cascade has aided a range of policy, pro-
grammes and research at multiple levels, we believe this cas-
cade can provide a framework to identify gaps in prevention
efforts and targets for interventions. We encourage this
approach to inform the intervention development and believe
this framework can support global efforts to reduce HIV inci-
dence.
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